Unraveling Cancer's Microbial Blueprint

Leveraging cutting-edge technologies and expertise, Creative Biolabs has looked into the intricate microbial composition of the gut microbiome for many years, to uncover unique signatures associated with oncological conditions. Our comprehensive approach combines advanced techniques. With our service, clients will gain invaluable insights into the complex interplay between gut microbiota and oncology, paving the way for personalized diagnostics and targeted therapeutic interventions.

Gut OncoMicrobiome Signatures (GOMS) as Next-generation Biomarkers

In the dynamic realm of cancer immunotherapy, identifying novel biomarkers is paramount for tailoring effective treatment strategies. Our company leads the charge in providing cutting-edge identification services for GOMS, poised to revolutionize cancer immunotherapy biomarker discovery.

Our gut oncomicrobiome signature Identification service integrates a diverse array of cutting-edge methodologies to discern precise microbial signatures pertinent to intestinal oncology. Our techniques encompass high-throughput sequencing, metagenomic analysis, metabolomics profiling, machine learning algorithms, as well as functional assays, and microbiome manipulation. Through these comprehensive approaches, we offer profound insights into the intricate microbial landscape of the gut microbiome concerning oncological conditions, thereby enabling tailored diagnostics and therapeutic strategies.

Through our pioneering approach, we offer clients comprehensive analysis and precise identification of GOMS, empowering clinicians and researchers with invaluable insights into the intricate interplay between the gut microbiome and cancer immunity. With our advanced techniques and expertise, we unlock the potential of GOMS as powerful biomarkers, driving forward the frontier of personalized cancer therapy.

Publications Sharing

Technology: Deep shotgun metagenomic sequencing

Journal: Nature Medicine

IF: 82.9

Research Findings:

In this groundbreaking investigation, the researchers embarked on a deep dive into the gut microbiome's role in predicting treatment response and prognosis among patients with diverse rare cancers undergoing combination immune checkpoint blockade (ICB) therapy. Through rigorous shotgun metagenomic sequencing of baseline fecal samples and a comprehensive meta-analysis, the study unearthed compelling evidence of the cross-cancer and cross-country validity of strain-response signatures within the gut microbiome. This crucial finding underscores the necessity of tailoring future endeavors in gut microbiome diagnostics and therapeutics according to the specific nuances of ICB treatment regimens rather than simply relying on cancer-type classifications.

In essence, this study represents a seminal contribution to the field, shedding new light on the potential of the gut microbiome as a predictive biomarker for cancer immunotherapy. It not only emphasizes the significance of strain-level microbial analysis but also advocates for a more nuanced approach in microbiome-based interventions, ultimately aiming to optimize treatment outcomes and redefine standards of care in the realm of oncology.

Fig.1 Phylogenetic tree of bacterial strains.¹

GOMS identification service at Creative Biolabs represents a pivotal advancement in the field of cancer research and personalized medicine. By leveraging state-of-the-art technologies and expertise, we empower researchers to unravel the complex interplay between the gut microbiome and cancer immunity. Through precise identification of GOMS, we provide invaluable insights that pave the way for tailored and effective cancer immunotherapy strategies. Please feel free to contact us to learn more about our GOMS identification service.

Reference

1. Gunjur, Ashray, et al. "A gut microbial signature for combination immune checkpoint blockade across cancer types." Nature Medicine (2024): 1-13.

For Research Use Only | Not For Clinical Use